Asian efforts in AIDS vaccine development step up

Regional efforts towards an AIDS vaccine must be strengthened and harmonized, says a new article in this week's PLoS Medicine Magazine. Yiming Shao from the National Center for AIDS/STD Control and Prevention in Beijing, China and colleagues from a range of Asian and international agencies announce the formation of AVAN-the AIDS Vaccine for Asia Network-that aims to strengthen its regional efforts in finding an AIDS vaccine.

The authors say that AVAN has been set up to help facilitate the development of a regional AIDS vaccine strategy that will: accelerate research and development of an AIDS vaccine through government advocacy, improved coordination and harmonization of research; develop clinical trial and manufacturing capacity; support ethical and regulatory frameworks; and ensure community participation.

More than 5 million people have already been infected with HIV across Asia, and another 500 million are considered at risk, say the authors.

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.